drugset / Trial / NCT04751929
Abemaciclib With or Without Atezolizumab for mCRPC
Phase 2
Completed
19 enrolled
Dana-Farber Cancer Institute
Eli Lilly and Company · collabGenentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and an immunotherapy drug called atezolizumab, alone or in combination, are effective in shrinking or preventing the growth of metastatic prostate cancer. The trial is also testing the safety of the combination of abemaciclib with atezolizumab.
Timeline
- Start
- 2021-08-20
- Primary completion
- 2024-06-17
- Completion
- 2025-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |